Sona Nanotech CEO David Regan joined Steve Darling from Proactive to announce a key regulatory milestone: the company has received approval from the Nova Scotia Health Research Ethics Board to conduct its proposed pilot human clinical trial for Targeted Hyperthermia Therapy (THT) in late-stage melanoma patients. Regan explained that the upcoming THT Pilot Study is being designed as a multi-centre clinical trial involving 30 to 40 patients. The trial remains contingent on receiving an Investigational Testing Authorization (ITA) from Health Canada for the medical device used in the therapy. The pilot study will build on insights from the company’s ongoing Early Feasibility Study, with the goal of further evaluating the safety and preliminary efficacy of Sona’s THT treatment. Regan emphasized that this next phase is essential for refining the protocol ahead of a potential larger-scale, randomized pivotal clinical trial, which would require additional regulatory approvals. Sona anticipates launching the pilot study in late 2025 or early 2026, marking a significant step forward in the company’s mission to bring its innovative nanoparticle-based cancer therapy closer to commercialization. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTherapy #GoldNanorods #FDAApproval #BiotechNews #Immunotherapy #ClinicalTrials #Nanomedicine #MelanomaTreatment #CancerResearch #THTTherapy #ClinicalTrials #CancerDevice #Immunotherapy #BiotechNews #LateStageCancer #ProactiveInvestors